计算溶液所需的质量、体积或浓度。
| 活性类型 | Relation | Activity value | Units | Action Type | 期刊 | PubMed Id | doi | Assay Aladdin ID |
|---|
Moligand™ 级 提供 ≥99% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Paquinimod (ABR 25757) is a specific and orally active inhibitor of S100A8/S100A9 . Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice
In Vivo
S100A9 is a calcium-binding protein of the S100 family. Paquinimod is an immunomodulatory compound preventing S100A9 binding to TLR-4. Prophylactic treatment with S100A9 inhibitor Paquinimod reduces pathology in experimental collagenase-induced osteoarthritis . Paquinimod is a potent inhibitor of insulitis and diabetes development in the NOD mouse. To assess the preventive efficacy of Paquinimod on diabetes development in female NOD mice, groups of mice are treated with daily doses of 0.04, 0.2, 1, and 5 mg/kg/day of Paquinimod from week 10 of age until week 20 of age. Glycosuria is analyzed on a weekly basis from 10 weeks of age until the endpoint of the experiment at 40 weeks of age. There is a clear dose-dependent reduction in diabetes development in the Paquinimod-treated mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal administration
Mice Female NOD/MrkTac mice are exposed to increasing concentration of CO 2 and upon loss of consciousness euthanized by cervical dislocation. To investigate the effect of the Q-compound Paquinimod on development of glycosuria and insulitis, mice are treated with Paquinimod dissolved in drinking water at different concentrations corresponding to daily doses of about 0.04, 0.2, 1, and 5 mg/kg body weight/day ). The mice are treated with Paquinimod starting from either 10 or 15 weeks of age. The duration of treatment varies from 5 to 23 weeks in the different experiments performed . aladdin has not independently confirmed the accuracy of these methods. They are for reference only.
Form:Solid
IC50& Target:S100A9
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 苯类化合物 |
| 类(Class) | 苯及其取代衍生物 |
| 亚类(Subclass) | 苯胺类 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 芳香族苯胺 |
| 其他上位类(Alternative Parents) | 喹啉-3-甲酰胺 氢化喹诺酮类药物 羟基喹啉 氢化喹啉 吡啶羧酸及其衍生物 羟基吡啶 吡啶酮类 叔羧酸酰胺 乙烯基酸 乙烯基酰胺 杂芳族化合物 内酰胺类 氮杂环化合物 有机氮化合物 有机氧化物 碳氢化合物衍生物 有机氧化合物 |
| 分子骨架(Molecular Framework) | 芳香族杂多环化合物 |
| 取代基(Substituents) | 芳香族苯胺 - 芳香族杂多环化合物 - 氮杂环 - 羧酰胺基 - 羧酸衍生物 - 二氢喹啉 - 二氢喹啉酮 - 杂芳香族化合物 - 烃衍生物 - 羟基吡啶 - 羟基喹啉 - 肟 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机杂环化合物 - 有机氮化合物 - 有机氧化合物 - 吡啶 - 吡啶羧酸或其衍生物 - 吡啶酮 - 喹啉胺 - 喹啉-3-甲酰胺 - 叔羧酸酰胺 - 乙烯基羧酸 - 乙烯酰胺 |
| 描述(Description) | 该化合物属于芳香族苯胺类有机化合物。这类芳香化合物含有苯胺基团,其中羧酰胺基被芳香基团取代。其通式为RNC(=O)R',其中R=苯基,R=芳香族基团。 |
| 外部描述符(External Descriptors) | 暂无 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|